PMID- 19265588
OWN - NLM
STAT- MEDLINE
DCOM- 20090707
LR  - 20211020
IS  - 1546-9549 (Electronic)
IS  - 1546-9530 (Linking)
VI  - 6
IP  - 1
DP  - 2009 Mar
TI  - Biventricular and novel pacing mechanisms in heart failure.
PG  - 14-8
AB  - Biventricular pacing, often referred to as cardiac resynchronization therapy 
      (CRT), improves subjective and objective measures and promotes reverse 
      ventricular remodeling in patients with chronic New York Heart Association (NYHA) 
      class III or IV heart failure despite optimal medical therapy, QRS duration of 
      more than 130 ms, and left ventricular ejection fraction of less than 35%. 
      However, there are many nonresponders and other patients who do not meet criteria 
      for CRT, limiting the efficacy of therapy. Recent investigations (eg, the REVERSE 
      trial) have shown that patients with minimal symptoms (NYHA class I-II) can 
      benefit from the mechanical and functional effects of CRT, specifically reverse 
      remodeling. Ongoing investigations include the possibility of earlier 
      intervention in the postinfarct period with CRT. Additionally, a novel pacing 
      mechanism known as cardiac contractility modulation has also shown promise in 
      improving remodeling of the failing heart. In this article, we review CRT's 
      effects on reverse remodeling in an expanding patient population and as a novel 
      pacing mechanism, its cardiac contractility modulation, and its benefits in 
      patients with heart failure.
FAU - Salazar, Christina
AU  - Salazar C
AD  - Ohio State University, 473 West 12th Avenue, Columbus, OH 43210, USA.
FAU - Abraham, William T
AU  - Abraham WT
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Heart Fail Rep
JT  - Current heart failure reports
JID - 101196487
SB  - IM
MH  - *Cardiac Pacing, Artificial
MH  - Female
MH  - Heart Failure/diagnosis/mortality/*therapy
MH  - Heart Function Tests
MH  - Humans
MH  - Male
MH  - *Pacemaker, Artificial
MH  - Prognosis
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Sensitivity and Specificity
MH  - Severity of Illness Index
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Ventricular Dysfunction, Left/diagnosis/mortality/*therapy
MH  - Ventricular Remodeling/*physiology
RF  - 41
EDAT- 2009/03/07 09:00
MHDA- 2009/07/08 09:00
CRDT- 2009/03/07 09:00
PHST- 2009/03/07 09:00 [entrez]
PHST- 2009/03/07 09:00 [pubmed]
PHST- 2009/07/08 09:00 [medline]
AID - 10.1007/s11897-009-0004-x [doi]
PST - ppublish
SO  - Curr Heart Fail Rep. 2009 Mar;6(1):14-8. doi: 10.1007/s11897-009-0004-x.